文献速递自身炎症与 IgG4 相关病

高效检测体细胞UBA1变异及预测VEXAS综合征患者变异的临床评分系统

Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究纳入89例临床疑似VEXAS综合征的日本患者,采用肽核酸钳制PCR联合常规PCR及Sanger测序检测体细胞UBA1变异,并建立基于年龄>50岁、皮肤病变、肺部受累、软骨炎和大细胞性贫血的临床评分系统,其预测UBA1变异阳性的曲线下面积为0.908。

要点

  • 联合常规PCR与肽核酸钳制PCR可高灵敏度、高特异性地检测体细胞UBA1变异。
  • 临床评分系统纳入年龄>50岁、皮肤病变、肺部受累、软骨炎和大细胞性贫血。
  • 评分总分预测UBA1变异患者的曲线下面积为0.908。

核心结论

  • 联合常规PCR与肽核酸钳制PCR的遗传筛查可高灵敏度、高特异性地检测体细胞UBA1变异。
  • 本临床评分系统可有效预测携带UBA1变异的患者。

研究设计与样本

  • 研究纳入89例临床疑似VEXAS综合征的日本患者,其中男性81例、女性8例,发病中位年龄69.3岁(四分位距62.1-77.6)。
  • 采用肽核酸钳制PCR、针对第3外显子聚集性UBA1变异的常规PCR及后续Sanger测序进行变异筛查。
  • 采用分区数字PCR或靶向扩增子深度测序评估变异等位基因频率(VAF)。
  • 建立临床评分系统预测UBA1变异阳性与阴性患者,并用受试者工作特征(ROC)曲线分析评估其诊断价值。

主要发现

  • 共鉴定出40例(44.9%)携带已报道致病性UBA1变异的患者,其中1例采用高灵敏度方法检出VAF为1.7%的变异。
  • 临床评分系统总分预测UBA1变异患者的曲线下面积为0.908。

关键数值与推荐

  • 临床评分系统纳入年龄>50岁、皮肤病变、肺部受累、软骨炎和大细胞性贫血。
  • 评分总分预测UBA1变异患者的曲线下面积为0.908。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To efficiently detect somatic UBA1 variants and establish a clinical scoring system predicting patients with pathogenic variants in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. METHODS: Eighty-nine Japanese patients with clinically suspected VEXAS syndrome were recruited [81 males and 8 females; median age of onset 69.3 years (interquartile range 62.1-77.6)]. Peptide nucleic acid-clamping PCR (PNA-PCR), regular PCR targeting exon 3 clustering UBA1 variants and subsequent Sanger sequencing were conducted for variant screening. Partitioning digital PCR or targeted amplicon deep sequencing was also performed to evaluate the variant allele frequency (VAF). We developed our clinical scoring system to predict UBA1 variant-positive and -negative patients and assessed the diagnostic value of our system using receiver operating characteristics (ROC) curve analysis. RESULTS: Forty patients (44.9%) with reported pathogenic UBA1 variants were identified, including a case having a variant with VAF of 1.7%, using a highly sensitive method. Our clinical scoring system considering age >50 years, cutaneous lesions, lung involvement, chondritis and macrocytic anaemia efficiently predicted patients with UBA1 variants (the area under the curve for the scoring total was 0.908). CONCLUSION: Genetic screening with the combination of regular PCR and PNA-PCR detected somatic UBA1 variants with high sensitivity and specificity. Our scoring system could efficiently predict patients with UBA1 variants.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Maeda A, Tsuchida N, Uchiyama Y, et al. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology (Oxford). 2024. PMID: 37606963. doi:10.1093/rheumatology/kead425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。